Aliasghar Valipour
Overview
Explore the profile of Aliasghar Valipour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piraee E, Azarbakhsh H, Mohammadyan G, Moftakhar L, Valipour A
Arch Iran Med
. 2024 Feb;
26(6):316-321.
PMID: 38310432
Background: Cardiovascular diseases (CVDs) are known as an important group of risk factor for progression of the Coronavirus-19 disease (COVID-19). The present study compared epidemiological features and outcomes in COVID-19...
2.
Azarbakhsh H, Moftakhar L, Valipour A, Mirahmadizadeh A, Moradi H, Piraee E
Health Sci Rep
. 2023 Sep;
6(9):e1499.
PMID: 37732104
Background And Aims: Some studies have shown that in addition to respiratory symptoms, gastrointestinal (GI) manifestations reported in patients with coronavirus disease 2019 (COVID-19). The aim of this study was...
3.
Epidemiological characteristics and outcomes of COVID-19 in asymptomatic versus symptomatic patients
Piraee E, Davoodi M, Valipour A, Ghojogh M, Jafari A, Azarbakhsh H
J Prev Med Hyg
. 2022 May;
62(4):E854-E858.
PMID: 35603235
Background: The clinical manifestations of COVID-19 are different, which can be attributed to asymptomatic carriers, acute respiratory disease and pneumonia with different severities. The aim of this study was to...
4.
Azarbakhsh H, Jokari K, Moftakhar L, Ghojogh M, Karimyan A, Salmanzadeh S, et al.
Med J Islam Repub Iran
. 2021 Dec;
35:116.
PMID: 34956962
COVID-19 spread rapidly throughout the world and affected many people. The purpose of this study was to investigate the epidemiological characteristics of patients with COVID-19 in southwest of Iran from...
5.
Moftakhar L, Piraee E, Abnavi M, Moftakhar P, Azarbakhsh H, Valipour A
Int J Hypertens
. 2021 Oct;
2021:7427500.
PMID: 34676114
Backgrounds: Individuals with hypertension are at higher risk of COVID-19 infection and related mortality. This study was carried out to assess the epidemiological features and predictors of mortality in patients...
6.
Hariri S, Rahimi Z, Hashemi-Madani N, Mard S, Hashemi F, Mohammadi Z, et al.
BMC Endocr Disord
. 2021 Jun;
21(1):135.
PMID: 34187451
Background: The Middle East and North Africa (MENA) is postulated to have the highest increase in the prevalence of diabetes by 2030; however, studies on the epidemiology of diabetes are...
7.
Zakavi I, Nayebifar S, Ghasemi E, Valipour A
Biomed Res Int
. 2021 May;
2021:5585077.
PMID: 33997019
Background: Fibrinogen and interleukin-1 as a proinflammatory cytokine and interleukin-10 and nesfatin-1 as an anti-inflammatory cytokine have an important role in the development and prevention of systemic inflammation and incidence...
8.
Moftakhar L, Moftakhar P, Piraee E, Ghaem H, Valipour A, Azarbakhsh H
Int J Diabetes Dev Ctries
. 2021 Feb;
41(3):383-388.
PMID: 33584062
Objectives And Background: People with diabetes (PWD) are one of the high-risk groups for coronavirus disease 2019 (COVID-19) infection, increasing the disease mortality. This study was aimed to compare the...
9.
Zakavi I, Nayebifar S, Ghasemi E, Valipour A
J Res Med Sci
. 2020 Dec;
25:86.
PMID: 33273931
Background: The application of supplements, herbal extracts, and exercise training for treatment of diseases and reducing chronic inflammation has been increased progressively among people. Thus, the aim of this investigation...
10.
Moosavi Jad S, Mohammadi H, Mohammadi M, Alizadeh R, Sarvarian M, Rastegarimehr B, et al.
Data Brief
. 2019 Nov;
26:103995.
PMID: 31709280
[This corrects the article DOI: 10.1016/j.dib.2017.09.031.].